{"id":55069,"date":"2023-03-22T11:04:21","date_gmt":"2023-03-22T10:04:21","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/wet-age-related-macular-degeneration-pipeline-insight-2023-comprehensive-analysis-on-80-upcoming-drugs-researchandmarkets-com\/"},"modified":"2023-03-22T11:04:21","modified_gmt":"2023-03-22T10:04:21","slug":"wet-age-related-macular-degeneration-pipeline-insight-2023-comprehensive-analysis-on-80-upcoming-drugs-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/wet-age-related-macular-degeneration-pipeline-insight-2023-comprehensive-analysis-on-80-upcoming-drugs-researchandmarkets-com\/","title":{"rendered":"Wet Age-Related Macular Degeneration – Pipeline Insight, 2023: Comprehensive Analysis on 80+ Upcoming Drugs – ResearchAndMarkets.com"},"content":{"rendered":"
\n

DUBLIN–(BUSINESS WIRE)–The “Wet Age-Related Macular Degeneration – Pipeline Insight, 2023”<\/a> clinical trials has been added to ResearchAndMarkets.com’s<\/strong> offering.\n<\/p>\n

<\/a><\/p>\n

\nThis report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in Wet Age-related Macular Degeneration pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.\n<\/p>\n

\nWet Age-related Macular Degeneration: Overview<\/strong>\n<\/p>\n

\nThe complaints of a patient with wet AMD may vary from metamorphopsia, central or paracentral scotoma, to a sudden, nonspecific reduction in central vision. Peripheral vision and color vision are generally unaffected; however, the patient may become legally blind (< 20\/200 vision) in the affected eye, particularly if AMD is not treated. Central vision loss can progress over weeks, even days, in a more rapid fashion compared with dry AMD. Patients with advanced late AMD can have geographic atrophy, neovascular AMD, features of both, or disciform scarring, which is the end-stage result of neovascular AMD. Rapid vision loss, usually over days to weeks, is more typical of wet AMD.\n<\/p>\n

\nAge-related macular degeneration is defined by fundus examination, but the diagnosis of AMD is typically based on age, clinical findings through various tests like Color fundus photography, Fluorescein angiography and\/or Optical coherence tomography. Color photography and fluorescein angiography are done when findings suggest wet AMD. The goals of wet AMD treatment are to slow progression, preserve existing vision, and reverse vision loss if possible. Management of Wet AMD is done through anti-VEGF medications, photocoagulation, and \/or photodynamic therapy.\n<\/p>\n

\nThe choice of other treatments depends on the size, location, and type of neovascularization. Anti-VEGF medications are the most effective and most common treatment for wet AMD. Patients with unilateral wAMD should take the daily nutritional supplements that are recommended for dry AMD to reduce the risk of AMD-induced vision loss in the other eye. Low vision rehabilitation can also be an effective part of a wet AMD treatment plan.\n<\/p>\n

\nThis report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Wet Age-related Macular Degeneration pipeline landscape is provided which includes the disease overview and Wet Age-related Macular Degeneration treatment guidelines. The assessment part of the report embraces, in depth Wet Age-related Macular Degeneration commercial assessment and clinical assessment of the pipeline products under development.\n<\/p>\n

\nIn the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Wet Age-related Macular Degeneration collaborations, licensing, mergers and acquisition, funding, designations and other product related details.\n<\/p>\n

\nReport Highlights<\/strong>\n<\/p>\n

\nThe companies and academics are working to assess challenges and seek opportunities that could influence Wet Age-related Macular Degeneration R&D. The therapies under development are focused on novel approaches to treat\/improve Wet Age-related Macular Degeneration.\n<\/p>\n

\nWet Age-related Macular Degeneration Emerging Drugs Chapters<\/strong>\n<\/p>\n

\nThis segment of the Wet Age-related Macular Degeneration report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.\n<\/p>\n

\nWet Age-related Macular Degeneration Emerging Drugs<\/strong>\n<\/p>\n

\nAbicipar pegol: Molecular Partners<\/strong>\n<\/p>\n

\nAbicipar pegol is a long-acting anti-VEGF therapeutic candidate, which was invented by Molecular Partners and initially licensed to Allergan in 2011. The program has been through two positive Phase III studies, CEDAR and SEQUOIA, which supported the non-inferior efficacy of the Abicipar quarterly dosing regimen to maintain vision gains with more than 50 percent fewer injections versus ranibizumab (13 vs. 6) dosed monthly in the first year. In June 2020, a Complete Response Letter was issued for the Biologics License Application for Abicipar pegol, indicating that the rate of intraocular inflammation observed following administration of Abicipar pegol resulted in an unfavorable benefit-risk ratio in the treatment of nAMD (AMD), and that additional work would be required to demonstrate a lower rate of ocular inflammation than what was previously seen in the Phase III studies. In 2021, Molecular Partners regained global rights to Abicipar from AbbVie and is determining appropriate next steps for the program.\n<\/p>\n

\nSOK583A1: Sandoz<\/strong>\n<\/p>\n

\nAflibercept binds and inhibits ocular VEGF-A and prevents abnormal growth of blood vessels in the choroid, impacting visual function. It improves visual acuity in patients with neovascular retinal diseases like nAMD, DME, and RVO. SOK583A1 is a biosimilar of Aflibercept (Eylea). It is currently in the Phase III stage of development for the treatment of wAMD and is being developed by Sandoz.\n<\/p>\n

\nBA9101 (LY09004): Shandong Boan Biotechnology Co. Ltd.<\/strong>\n<\/p>\n

\nBA9101 (LY09004), a biosimilar for Eylea, is a recombinant human vascular endothelial growth factor receptor-antibody fusion protein ophthalmic injection, indicated for neovascular (wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME) and diabetic retinopathy (DR) in patients with diabetic macular edema, and visual impairment due to pathological myopia secondary to choroidal neovascularization(PM-CNV). As a soluble decoy receptor, LY09004 can bind to cytokines such as VEGF-A, VEGF-B and P1GF, inhibit the downstream signaling pathway of VEGFR, inhibit neovascularization, and reduce vascular permeability, thereby treating pathological neovascularization of the retina and choroid eye diseases.\n<\/p>\n

\nADVM-022: Adverum Biotechnologies<\/strong>\n<\/p>\n

\nADVM-022 is a recombinant, replication-deficient adeno virus-associated (AAV) gene therapy. ADVM-022 utilizes a propriety vector capsid, AAV.7m8, carrying an aflibercept coding sequence under the control of a proprietary expression cassette. ADVM-022 (AAV.7m8-aflibercept) is administered as a single, in-office intravitreal (IVT) injection, designed to deliver long-term efficacy and reduce the burden of frequent anti-VEGF injections, optimize patient compliance and improve vision outcomes for patients with wet AMD and DME. The therapeutic candidate is in Phase II clinical studies for wet AMD.\n<\/p>\n

\nWet Age-related Macular Degeneration: Therapeutic Assessment<\/strong>\n<\/p>\n

\nThis segment of the report provides insights about the different Wet Age-related Macular Degeneration drugs segregated based on following parameters that define the scope of the report, such as:\n<\/p>\n

\nMajor Players in Wet Age-related Macular Degeneration<\/strong>\n<\/p>\n

\nThere are approx. 75+ key companies which are developing the therapies for Wet Age-related Macular Degeneration. The companies which have their Wet Age-related Macular Degeneration drug candidates in the most advanced stage, i.e. Preregistration include, Molecular Partners.\n<\/p>\n

\nWet Age-related Macular Degeneration pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as<\/strong>\n<\/p>\n